result question manag
summari result
poor quarter lfl sale growth factset consensu materi gross
margin compress yoy materi ebit margin compress yoy
sale perform weak widespread segment except
fabric come materi expect save grace core
ep come ahead bloomberg consensu consequ non-
 expect return posit price point price expect
remain neg
reduc ep
activist activist easi solut estim ebit gener
rate target price
maintain under-perform rate target price move
question manag
price expect continu declin absent one-off impact pleas explain
gross margin expect expand
april
exan bnpp estim thomson reuter consensu list currenc dividend reinvest
date time london time invest recommend finalis may differ date time broad
dissemin websit see appendix analyst certif import disclosur non-u research analyst disclosur
result question
summari result
poor quarter lfl sale growth factset consensu
materi gross margin compress yoy materi ebit margin
mix growth price declin
scan top-lin driver categori except fabric
segment materi expect particular note rel
expect
health vs ebnpp comment oral declin
low singl digit due inventori price reduct
beauti vs ebnpp comment flat sale hair
save grace quarter core ep come ahead
figur outlin main element releas rel
consensu expect
figur summari result rel expect
varianc
figur outlin main element gs revis previou
figur summari guidanc
scope/fx impact sale
low end
market growth estim market growth around mid-singl
digit growth emerg market low-singl digit growth develop market
overal market growth rate larg unchang
share overal volum valu share trend continu improv volum share
in-lin py consequ improv emerg
develop market gs categori grow hold volum
share gs valu share decreas adjust inter-categori mix
impact reduc
tough market sever larg busi current difficult market
saudi arabia egypt nigeria brazil collect market pose
tough categori gs perform babi groom
want exclud categori sale growth
profit growth fiscal ytd groom babi take longer acceler
need chang improv
growth countri achiev mid-singl digit growth greater
china declin two year ago fiscal ytd franc
philippin high-singl digit growth russia mid- high-singl digit growth
japan double-digit growth india turkey
categori growth categori growth vari markedli market good
china pick india us difficult stabl volum price
tough market categori growth stabl modestli improv saudi arabia
contract great deal given econom transit europ stabl slightli
improv brazil difficult improv futur mexico stabl
russia impact extern event anyth outsid
like strengthen consum demand
e-commerc e-commerc grew fiscal ytd grow hold
share categori
lfl guidanc expect achiev low end lfl guidanc
rang fy potenti round
price expect return posit price point although
price expect remain neg make adjust
offer consum valu done groom strategi
trade consum pant premium-tap diaper babi
margin sinc amount price neg lessen time
gillett price reduct annualis cost save tend back-end weight
 feel reason confid grow gross ebit margin
object clearli gross ebit margin expans
headwinds/tailwind expect commod after-
tax headwind transport after-tax headwind fx
growth roughli quarter
gillett price impact gillett price adjust neg impact
quarter impact annualis start april henc expect
groom start acceler
groom see posit progress us male shave grew volum
consecut quarter male shave system volum
grow volum valu share us past month
period consum enter ladder evid gillett
experi better trade consum pleas
perform product enter open idea brand
lose strategi target smaller smaller group consum
faster growth segment premium super premium new form natur
fastest grow segment across busi
inventori trade inventori reduct primarili us reduc lfl sale
us privat label diaper see acceler instor support
privat label diaper part due retail endeavour combat lidl aldi
amazon huge dynam categori influenc behaviour
retail
merck/teva clear teva structur jv
chang partnership termin juli time merck
complement over-the-counter attract space merck add
around sale primarili europ latin america asia gs exist
busi gener sale deliv profit mid-singl digit growth
vick alon gener sale impact
earn either jv termin merck acquisit merck deal close
end neutral ep accret
over-the-counter trend mega trend drive market age popul
well consum take control health well
 role core growth come organ sale profit growth within
exist portfolio think key stay focus core
categori look way leverag adjac fair say
like open recent past consequ
portfolio prune finish
pfizer consum comment
retail pressur new phenomenon privat label expand
europ perform well built share
return sharehold return buyback
dividend full year expect pay nearli
dividend repurchas share rang aggreg
return valu sharehold
tax core effect tax rate expect
lower previou outlook
agenc take big step chang work agenc
pioneer new approach achiev greater product non-work
market gone agenc plan
move agenc fixed/flow model fix retain
core agenc supplement float agenc in-and-out basi
insourc media plan focus media wast
figur outlin revis previou ep estim
figur summari ep revis
activist activist easi solut estim ebit
gener develop market
rate target price
maintain under-perform rate
deriv hpc sector valuat benchmark consid histor valuat
sector rel market differ interest rate environ see figur
figur eu hpc price-to-earnings rel market vs us year yield
consid histor relationship abl undertak regress analysi
build model determin valuat hpc sector benchmark
differ valuat interest rate context last undertook
exercis see unmov deriv benchmark price-to-earnings light recent
pullback us year yield market deriv benchmark price-to-earnings
previous argu see mind eye trade price-to-earnings
discount hpc benchmark multipl price-to-earnings precis continu
believ discount warrant light princip culprit
two major sector concern low top-lin growth gross margin pressur see
golden rule bit gross believ price-to-earnings point discount warrant
keep mind revis target multipl price-to-earnings
consequ appli price-to-earnings revis ep ep
target price move maintain under-perform rate
question manag
price expect continu declin absent one-off impact
pleas explain gross margin expect expand
assum abl stabilis aggreg market share would still
absent market acceler grow think
financi model go forward assum market acceler share
gain ye
appear adam plan-b requir assum materi
improv organ perform forthcom long
wait might reconsid view
third categori fall problem child territori categori
given amount chang claim take place within organis
risk acquisit merck consum healthcar busi place
undu strain upon organis
seemingli creat valu merck consum healthcar
other meaning consum healthcar footprint
pleas explain disband teva jv work practic
perceiv risk
nelson peltz outlin number idea white paper
idea activ pursu ye pleas shed colour
extent fabric busi benefit quarter
system process difficulti prompt henkel recent caution calendar
big focu gross margin busi featur way
compens metric
materi acquisit merck consum healthcar seem obviou
remedi growth frustrat someth date
will consid
proport new save programm alreadi
achiev proport remain outstand
number peer appear start creat brand
loreal unilev strategi consid
irresist superior admir strategi pleas explain
quickli achiev step chang irresist product
long multi-year project
given entireti execut team veteran
think organis would much benefit presenc someon
outsid experi
pleas see overleaf revis segment sale profit loss account
fabric
babi feminin famili
profit taxat non-gaap
profit tax
tax pbt
tax pbt non-gaap
profit continu oper non-gaap
profit continu oper
profit discontinu oper
net profit attribut procter gambl
dividend payment prefer share
basic number share averag
fulli dilut number share averag
pay-out ratio basic non-gaap
dividend cover basic non-gaap
chg ebit non-gaap
depreci amortis
chg ebitda non-gaap
invest case valuat risk
activist activist easi solut estim ebit
gener develop market
valu price-to-earnings price-to-earnings
upsid
risk would highlight includ possibl activist nelson peltz drive
posit chang anticip
downsid
risk would highlight includ possibl stock continu de-rat
investor increas question abil reignit organ sale growth
